UBS analyst Priya Sachdeva reiterated a Buy rating and $105.00 price target on Boston Scientific (NYSE: BSX).

The analyst commented, "BSX presented data from the highly-anticipated CHAMPION-AF trial. While the study hit all endpoints and is seen as a positive as it now removes some headline risk, we expect BSX shares to likely see just modest share appreciation on the day tomorrow as we think questions surrounding (1) timing and magnitude of contribution from CHAMPION still remain, and (2) nearterm EP growth sustainability concerns have yet to abate and are likely to pressure sentiment until 1Q earnings. Ultimately, with shares still trading at a discount vs. peers -- and down nearly 25% YTD -- we remain bullish on BSX's ability to sustain recent strong double-digit top-line momentum in-line with their LRP of ~10%+ sales CAGR and see now as an attractive opportunity for investors to enter the name."

For an analyst ratings summary and ratings history on Boston Scientific click here. For more ratings news on Boston Scientific click here.

Shares of Boston Scientific closed at $62.93 yesterday.